COvid-19 vaccination and Biomarkers in cirrhosis And post-Liver Transplantatio

Phase 4

Completed

• Conditions: Coronavirus infection; Covid-19; 10019654; 10047438

• Registration Number: NL-OMON51899
• Lead Sponsor: eids Universitair Medisch Centrum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 22 July 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 120

Inclusion Criteria

i) Participant able to give written informed consent
ii) Diagnosis of:
a. Cirrhosis (on imaging or liver biopsy), or,
b. Autoimmune liver disease (PSC, PBC or AIH) without cirrhosis, or
c. Post-LT for cirrhosis >6 months, or
d. Healthy participant (absence of severe and uncontrolled cardiac,
respiratory, liver,
renal or endocrine disease in opinion of PI or sub-I, see appendix 1).
iii) Age >18 years

Exclusion Criteria

i) History of Covid-19 (PCR-positive episode)
ii) Participant unable to give written informed consent
iii) Uncontrolled HIV infection

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified